Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Incyte Corporation INCY
$64.88
+$0.72 (1.11%)
На 18:00, 12 мая 2023
+36.14%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
14215167360.00000000
-
week52high
86.29
-
week52low
63.48
-
Revenue
3394635000
-
P/E TTM
43
-
Beta
0.71522400
-
EPS
1.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
31 июл 2023 г. в 11:00
Описание компании
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 03 авг 2022 г. |
| Guggenheim | Neutral | Buy | 03 авг 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 03 авг 2022 г. |
| Wells Fargo | Equal-Weight | 28 июл 2022 г. | |
| SVB Leerink | Underperform | Underperform | 20 июл 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 18 окт 2022 г. |
| JP Morgan | Neutral | Neutral | 24 окт 2022 г. |
| RBC Capital | Outperform | Outperform | 02 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 02 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 03 янв 2023 г. |
| Piper Sandler | Overweight | 31 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pasquale Maria E | D | 0 | 802 | 31 янв 2023 г. |
| Pasquale Maria E | D | 68524 | 802 | 31 янв 2023 г. |
| Pasquale Maria E | A | 69326 | 802 | 31 янв 2023 г. |
| Pasquale Maria E | D | 0 | 4842 | 30 янв 2023 г. |
| Pasquale Maria E | D | 68524 | 4842 | 30 янв 2023 г. |
| Pasquale Maria E | A | 73366 | 4842 | 30 янв 2023 г. |
| Pasquale Maria E | A | 74168 | 5644 | 30 янв 2023 г. |
| Pasquale Maria E | A | 82898 | 14374 | 30 янв 2023 г. |
| Pasquale Maria E | A | 80385 | 11861 | 30 янв 2023 г. |
| Pasquale Maria E | A | 78962 | 10438 | 30 янв 2023 г. |
Новостная лента
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
Zacks Investment Research
02 мая 2023 г. в 16:51
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
Incyte (INCY) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
02 мая 2023 г. в 09:54
Incyte (INCY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.55 per share a year ago.
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
Zacks Investment Research
26 апр 2023 г. в 12:11
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Incyte (INCY) Opzelura Gets EC Nod for Non-Segmental Vitiligo
Zacks Investment Research
21 апр 2023 г. в 14:26
Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).